Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,356 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Gene Expression Clear all
Completed No phase listed Observational Accepts healthy volunteers

Effect of Glucose Load on Expression of Advanced Glycation End Products in Women Screened for Gestational Diabetes

NCT03029546
View directory record Official record
Conditions
Inflammation
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Oct 19, 2026, 4:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nitric Oxide and the Autonomic Nervous System

NCT00178919
View directory record Official record
Conditions
Hypertension, Pure Autonomic Failure
Interventions
L-NMMA, Trimethaphan
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 19, 2026, 4:04 PM EDT
Recruiting Not applicable Interventional

A Frequency-Modulated Music Intervention to Enhance Cognitive Processing Therapy (CPT) for PTSD

NCT06925867
View directory record Official record
Conditions
PTSD - Post Traumatic Stress Disorder
Interventions
Frequency Filtered Music, Unfiltered Music, Cognitive Processing Therapy for PTSD
Other · Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Columbus, Ohio • Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 19, 2026, 4:04 PM EDT
Completed No phase listed Observational

Studying Tumor Tissue Samples From Patients With Early-Stage Non-Small Cell Lung Cancer

NCT01517971
View directory record Official record
Conditions
Lung Cancer
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 19, 2026, 4:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Five Selected Markers in Skin Biopsies of Patients With Postherpetic Neuralgia and Healthy Controls

NCT01379716
View directory record Official record
Conditions
Postherpetic Neuralgia, Healthy Age/Gender Matched Volunteers
Interventions
skin biopsy
Other
Lead sponsor
Albany Medical College
Other
Eligibility
50 Years to 95 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 19, 2026, 4:04 PM EDT
Completed Phase 1 Interventional

Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies

NCT05694364
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Triple Negative Breast Cancer Malignancies
Interventions
Fludarabine, Cyclophosphamide, PRGN-3007
Drug · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 19, 2026, 4:04 PM EDT
Terminated No phase listed Observational

Characterizing Fatigue Experienced by Cancer Patients Receiving Primary Treatment and Cancer Survivors

NCT01231932
View directory record Official record
Conditions
Cancer, Fatigue, Prostate Cancer, Breast Cancer, Cancer Survivor
Interventions
Not listed
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
18 Years to 120 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 19, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers

NCT02123849
View directory record Official record
Conditions
Lung Carcinoma, Tobacco Use Disorder
Interventions
Aspirin, Laboratory Biomarker Analysis, Placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
2
States / cities
Tucson, Arizona • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 19, 2026, 4:04 PM EDT
Completed Phase 1 Interventional Results available

This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.

NCT03156114
View directory record Official record
Conditions
Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions
Ezabenlimab, BI 754111
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
6
States / cities
Miami, Florida • Sarasota, Florida • Hackensack, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 19, 2026, 4:04 PM EDT
Completed No phase listed Observational

Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia

NCT01460238
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Oct 19, 2026, 4:04 PM EDT
Completed Not applicable Interventional

Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia

NCT00142155
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Rituximab, monoclonal antibodies
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
30 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 19, 2026, 4:04 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

NCT06295159
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma, Melanoma
Interventions
Nivolumab, Nivolumab + Relatlimab, Ipilimumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 19, 2026, 4:04 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

NCT06051695
View directory record Official record
Conditions
Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer, NSCLC, Recurrent, Non-Small Cell Squamous Lung Cancer, Pancreas Cancer, Pancreatic Neoplasm, Colorectal Adenocarcinoma, CRC, Colon Cancer, Rectal Cancer, Cancer, Ovarian Cancer, Ovarian Neoplasms, Mesothelioma, Mesothelioma, Malignant, Ovary Cancer, Lung Cancer, MESOM
Interventions
A2B694, A2B543, xT CDx with HLA-LOH Assay
Biological · Diagnostic Test
Lead sponsor
A2 Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
12
States / cities
Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 19, 2026, 4:04 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effect Of Vitamin D On Measures Of Bone Health And Gene Expression

NCT01696409
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
400 IU vitamin D3, 2000 IU vitamin D3
Dietary Supplement
Lead sponsor
Boston University
Other
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 19, 2026, 4:04 PM EDT
Completed No phase listed Observational

ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.

NCT00618267
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2010 · Synced Oct 19, 2026, 4:04 PM EDT
Withdrawn Phase 2 Interventional

Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

NCT04329221
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma, Actinic Keratoses, Skin Cancer, Organ Transplant Recipients, Immunotherapy
Interventions
Calcipotriol Only Product in Cutaneous Dose Form, Vaseline, Topical 5FU
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Oct 19, 2026, 4:04 PM EDT
Withdrawn Phase 2 Interventional

Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1

NCT01524575
View directory record Official record
Conditions
Metastatic Pancreatic Cancer, ERCC1
Interventions
gemcitabine and oxaliplatin
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 19, 2026, 4:04 PM EDT
Completed No phase listed Observational

Sensory Study: Taste and Tongue Biology

NCT05985928
View directory record Official record
Conditions
Healthy Adults
Interventions
Not listed
Lead sponsor
University of Massachusetts, Amherst
Other
Eligibility
18 Years to 45 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Amherst, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 19, 2026, 4:04 PM EDT
Terminated No phase listed Observational

Anti-inflammatory Agents and Cholesterol Metabolism

NCT01279395
View directory record Official record
Conditions
Osteoarthritis
Interventions
Not listed
Lead sponsor
Winthrop University Hospital
Other
Eligibility
40 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2019 · Synced Oct 19, 2026, 4:04 PM EDT
Completed No phase listed Observational

Relationship Between Mitochondrial Dysfunction and Fatique in Cancer Patients Following External Beam Radiation Therapy

NCT01143467
View directory record Official record
Conditions
Cancer, Fatigue
Interventions
Not listed
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
18 Years to 100 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 19, 2026, 4:04 PM EDT
Completed Not applicable Interventional

Molecular Profiling for Individualized Treatment Plan for DIPG

NCT02274987
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma (DIPG)
Interventions
Specialized tumor board recommendation, Standard radiation therapy
Other · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 25 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
5
States / cities
San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 19, 2026, 4:04 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)

NCT04439188
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
PI3K-beta Inhibitor GSK2636771
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 19, 2026, 4:04 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers in Patients With Head and Neck Cancer and in Healthy Volunteers

NCT00899769
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
protein expression analysis, proteomic profiling, immunoenzyme technique, laboratory biomarker analysis, liquid chromatography, mass spectrometry
Genetic · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 19, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy of PEAR-004 in Schizophrenia

NCT03751280
View directory record Official record
Conditions
Schizophrenia
Interventions
PEAR-004, Sham
Device
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Garden Grove, California • Oakland, California • Torrance, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 19, 2026, 4:04 PM EDT